Uric Acid Level Interpreter

What Uric Acid Tells You

Uric acid is the end product of purine metabolism in humans. Purines come from both endogenous breakdown of cells and from dietary sources, particularly animal proteins. In most other mammals, uric acid is broken down further by the enzyme uricase; humans lost functional uricase during primate evolution, and as a result we carry uric acid levels several times higher than other animals. Roughly two-thirds of urate is excreted by the kidneys and the remainder by the gut.

When serum urate exceeds the saturation point for monosodium urate — approximately 6.8 mg/dL (405 µmol/L) — crystals can deposit in joints and soft tissues. Those crystals are the physical basis of gout, the most common inflammatory arthritis. High urate is also a recognised cardiovascular and renal risk marker, although causality remains debated.

Reference Ranges by Sex

Multiply mg/dL by 59.48 to convert to µmol/L. Cutoffs reflect commonly used reference ranges and the biochemical definition of hyperuricemia.

Hyperuricemia vs Gout

It is worth being precise about language. Hyperuricemia is the biochemical state of having serum uric acid above the normal range. Gout is a clinical diagnosis requiring joint inflammation caused by monosodium urate crystal deposition — most classically the first metatarsophalangeal joint (the big toe), but any joint can be affected. Many people have hyperuricemia for years or decades without ever developing gout; many gout flares occur near the saturation threshold; and urate can transiently drop during a flare because inflammatory cytokines alter urate handling.

For someone with confirmed gout, the ACR 2020 Guideline for the Management of Gout (FitzGerald JD et al., Arthritis & Rheumatology 2020) recommends urate-lowering therapy targeting serum urate below 6 mg/dL (360 µmol/L), or below 5 mg/dL (300 µmol/L) for patients with tophi or frequent flares. For asymptomatic hyperuricemia, routine pharmacologic lowering is generally not recommended.

Dietary Triggers

Several dietary factors have strong and consistent associations with higher serum urate and gout risk:

• Organ meats (liver, kidney, sweetbreads) — very high purine content.
• Certain seafood — anchovies, sardines, mackerel, herring, mussels.
• Alcohol, especially beer — beer combines ethanol (which reduces urinary urate excretion) with purines from yeast; spirits to a lesser extent; wine modestly.
• Fructose, particularly high-fructose corn syrup — found in many sugar-sweetened soft drinks and processed foods; accelerates urate production via ATP depletion in the liver.
• Red meat and game — moderate but consistent effect.

Conversely, several dietary factors are associated with lower urate: dairy (particularly low-fat), coffee, cherries, and vitamin C. A Mediterranean or DASH-style diet pattern consistently performs well in gout-risk studies. Dietary change typically lowers serum urate by about 1 mg/dL — useful but usually not sufficient when urate is far above target.

Medications That Raise Uric Acid

A significant fraction of hyperuricemia in older adults is drug-related. Common contributors:

• Thiazide and loop diuretics (hydrochlorothiazide, furosemide) — reduce urinary urate excretion.
• Low-dose aspirin (below about 2 g/day) — reduces urate excretion; the cardiovascular benefit usually outweighs this for patients who need it.
• Cyclosporine and tacrolimus — post-transplant.
• Pyrazinamide and ethambutol — anti-tuberculosis drugs.
• Niacin at pharmacologic doses — lipid-lowering use.

On the other side, several commonly prescribed drugs lower uric acid, which matters when choosing therapy for someone with gout:

• Losartan (and, less consistently, some other ARBs) — has a mild uricosuric effect.
• Fenofibrate — lipid-lowering with mild urate reduction.
• SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) — lower serum uric acid by ~0.5–1 mg/dL via increased urinary excretion; observational data show reduced gout flare incidence in type 2 diabetes.

Kidney Function Matters

Because the kidneys excrete about two-thirds of uric acid, chronic kidney disease (CKD) is a major driver of hyperuricemia. As eGFR falls, the kidneys retain more urate, and many CKD patients are hyperuricemic without gout. Conversely, hyperuricemia is associated with faster CKD progression in observational data, though trials of urate lowering for renal protection have produced mixed results. If uric acid is persistently elevated, checking kidney function with creatinine and eGFR is reasonable.

Treatment Options (Discuss With Your Doctor)

For patients in whom gout is diagnosed and urate-lowering therapy is indicated, the ACR 2020 guideline preferences are:

• Allopurinol — first-line xanthine oxidase inhibitor. Starts at a low dose (often 100 mg/day or lower in CKD) and titrates to target. HLA-B*5801 screening is recommended in patients of Southeast Asian or Black descent given the rare but serious hypersensitivity syndrome risk.
• Febuxostat — alternative xanthine oxidase inhibitor for patients intolerant of allopurinol. The CARES and FAST trials have produced different cardiovascular signals; risk/benefit should be individualised.
• Probenecid — uricosuric, less common in CKD.
• Pegloticase — for refractory cases; IV recombinant uricase.